Symbols / AEMD $2.34 Aethlon Medical, Inc.
AEMD Chart
About
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
Fundamentals
Scroll to Statements| Market Cap | 3.67M | Enterprise Value | -3.46M | Income | -11.52M | Sales | — | Book/sh | 6.90 | Cash/sh | 5.29 |
| Dividend Yield | — | Payout | 0.00% | Employees | 9 | IPO | — | P/E | — | Forward P/E | -2.39 |
| PEG | — | P/S | — | P/B | 0.34 | P/C | — | EV/EBITDA | 0.49 | EV/Sales | — |
| Quick Ratio | 5.53 | Current Ratio | 5.68 | Debt/Eq | 6.22 | LT Debt/Eq | — | EPS (ttm) | -48.46 | EPS next Y | -0.98 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-02-12 | ROA | -62.88% | ROE | -208.60% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.57M | Shs Float | 1.24M | Short Float | 0.90% |
| Short Ratio | 0.18 | Short Interest | — | 52W High | 35.20 | 52W Low | 1.36 | Beta | 1.52 | Avg Volume | 51.41K |
| Volume | 131.00 | Target Price | $4.75 | Recom | None | Prev Close | $0.00 | Price | $2.34 | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.75
Mean price target
2. Current target
$2.47
Latest analyst target
3. DCF / Fair value
$-52.14
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.47
Low
$1.50
High
$8.00
Mean
$4.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-14 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2025-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-19 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-06-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-03-04 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-10-24 | main | HC Wainwright & Co. | Buy → Buy | $23 |
- Cancer and infection treatment developer Aethlon explores deals with Maxim - Stock Titan hu, 12 Mar 2026 07
- Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Gains on News - Investorideas.com hu, 12 Mar 2026 07
- Aethlon Medical enacts 1-for-10 reverse stock split effective Thursday - Investing.com hu, 16 Oct 2025 07
- Why Is Aethlon Medical Stock (AEMD) Up 60% Today? - TipRanks hu, 21 Aug 2025 07
- Aethlon Medical (AEMD) director forfeits 178 shares to cover RSU taxes - Stock Titan Wed, 01 Apr 2026 07
- Aethlon Medical’s Stock Surge Raises Eyebrows - StocksToTrade hu, 21 Aug 2025 07
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 16
- Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) on the Move – Morning High of $2.09 - Investorideas.com Fri, 13 Mar 2026 07
- Aethlon Medical hires Maxim Group to explore strategic options - Investing.com hu, 12 Mar 2026 07
- Cancer device study moves forward after reviewers find no safety issues - Stock Titan ue, 24 Mar 2026 07
- Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity - TipRanks ue, 17 Mar 2026 07
- Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review - Investorideas.com ue, 24 Mar 2026 15
- aethlon medical announces reverse stock split effective june 6 - Investing.com hu, 05 Jun 2025 07
- Director at Aethlon (NASDAQ: AEMD) forfeits shares to cover taxes - Stock Titan Wed, 01 Apr 2026 07
- Medical Tech Stock Aethlon Medical's (NASDAQ: AEMD) Australian Oncology Clinical Trial Update and Progress - Investorideas.com ue, 07 Oct 2025 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
0.57
+95.21%
|
0.29
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
0.57
+95.21%
|
0.29
|
| Operating Expense |
|
9.34
-26.08%
|
12.64
+1.31%
|
12.47
+16.41%
|
10.72
|
| Selling General And Administration |
|
9.34
-26.08%
|
12.64
+1.31%
|
12.47
+16.41%
|
10.72
|
| General And Administrative Expense |
|
9.34
-26.08%
|
12.64
+1.31%
|
12.47
+16.41%
|
10.72
|
| Salaries And Wages |
|
3.87
-25.59%
|
5.21
+17.17%
|
4.44
-3.94%
|
4.63
|
| Other Gand A |
|
5.47
-26.42%
|
7.43
-7.46%
|
8.03
+31.86%
|
6.09
|
| Total Expenses |
|
9.34
-26.08%
|
12.64
+1.31%
|
12.47
+16.41%
|
10.72
|
| Operating Income |
|
-9.34
+26.08%
|
-12.64
-6.20%
|
-11.90
-14.18%
|
-10.42
|
| Total Operating Income As Reported |
|
-9.34
+26.08%
|
-12.64
-6.20%
|
-11.90
-14.18%
|
-10.42
|
| EBITDA |
|
-13.04
-6.20%
|
-12.28
-5.32%
|
-11.66
-13.21%
|
-10.30
|
| Normalized EBITDA |
|
-13.04
-6.20%
|
-12.28
-6.62%
|
-11.52
-11.83%
|
-10.30
|
| Reconciled Depreciation |
|
0.34
-5.43%
|
0.36
+49.05%
|
0.24
+94.76%
|
0.12
|
| EBIT |
|
-13.38
-5.87%
|
-12.64
-6.20%
|
-11.90
-14.18%
|
-10.42
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-0.14
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-0.14
|
0.00
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-0.14
|
0.00
|
| Net Income |
|
-13.39
-9.66%
|
-12.21
-1.48%
|
-12.03
-15.49%
|
-10.42
|
| Pretax Income |
|
-13.39
-9.66%
|
-12.21
-1.48%
|
-12.03
-15.44%
|
-10.42
|
| Net Non Operating Interest Income Expense |
|
0.29
-35.62%
|
0.45
+3976.88%
|
0.01
|
0.00
|
| Interest Expense Non Operating |
|
0.01
|
—
|
—
|
—
|
| Net Interest Income |
|
0.29
-35.62%
|
0.45
+3976.88%
|
0.01
|
0.00
|
| Interest Expense |
|
0.01
|
—
|
—
|
—
|
| Interest Income Non Operating |
|
0.30
-33.36%
|
0.45
+3976.88%
|
0.01
|
0.00
|
| Interest Income |
|
0.30
-33.36%
|
0.45
+3976.88%
|
0.01
|
0.00
|
| Other Income Expense |
|
-4.33
-22760.13%
|
-0.02
+86.66%
|
-0.14
|
—
|
| Other Non Operating Income Expenses |
|
-4.33
-22760.13%
|
-0.02
|
—
|
—
|
| Gain On Sale Of Business |
|
—
|
0.00
+100.00%
|
-0.14
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-13.39
-9.66%
|
-12.21
-1.48%
|
-12.03
-15.44%
|
-10.42
|
| Net Income From Continuing Operation Net Minority Interest |
|
-13.39
-9.66%
|
-12.21
-1.48%
|
-12.03
-15.49%
|
-10.42
|
| Net Income From Continuing And Discontinued Operation |
|
-13.39
-9.66%
|
-12.21
-1.48%
|
-12.03
-15.49%
|
-10.42
|
| Net Income Continuous Operations |
|
-13.39
-9.66%
|
-12.21
-1.48%
|
-12.03
-15.44%
|
-10.42
|
| Minority Interests |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Normalized Income |
|
-13.39
-9.66%
|
-12.21
-2.70%
|
-11.89
-14.13%
|
-10.42
|
| Net Income Common Stockholders |
|
-13.39
-9.66%
|
-12.21
-1.48%
|
-12.03
-15.49%
|
-10.42
|
| Diluted EPS |
|
-8.58
+97.79%
|
-388.80
-723.73%
|
-47.20
+16.90%
|
-56.80
|
| Basic EPS |
|
-8.58
+97.79%
|
-388.80
-723.73%
|
-47.20
+16.90%
|
-56.80
|
| Basic Average Shares |
|
1.56
+396.93%
|
0.31
+22.35%
|
0.26
+39.17%
|
0.18
|
| Diluted Average Shares |
|
1.56
+396.93%
|
0.31
+22.35%
|
0.26
+39.17%
|
0.18
|
| Diluted NI Availto Com Stockholders |
|
-13.39
-9.66%
|
-12.21
-1.48%
|
-12.03
-15.49%
|
-10.42
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 |
|---|---|---|---|
| Total Assets |
|
7.36
-10.75%
|
8.25
|
| Current Assets |
|
5.95
-4.43%
|
6.23
|
| Cash Cash Equivalents And Short Term Investments |
|
5.50
+1.09%
|
5.44
|
| Cash And Cash Equivalents |
|
5.50
+1.09%
|
5.44
|
| Cash Equivalents |
|
5.16
+8.90%
|
4.74
|
| Cash Financial |
|
0.34
-51.33%
|
0.71
|
| Receivables |
|
—
|
—
|
| Accounts Receivable |
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
| Current Deferred Assets |
|
0.00
-100.00%
|
0.28
|
| Other Current Assets |
|
0.45
-11.35%
|
0.51
|
| Total Non Current Assets |
|
1.41
-30.22%
|
2.02
|
| Net PPE |
|
1.28
-32.67%
|
1.90
|
| Gross PPE |
|
2.26
-21.87%
|
2.89
|
| Accumulated Depreciation |
|
-0.98
+1.18%
|
-0.99
|
| Properties |
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
| Machinery Furniture Equipment |
|
0.76
-31.52%
|
1.11
|
| Other Properties |
|
0.60
-31.84%
|
0.88
|
| Leases |
|
0.89
+0.00%
|
0.89
|
| Goodwill And Other Intangible Assets |
|
0.00
-50.00%
|
0.00
|
| Other Intangible Assets |
|
0.00
-50.00%
|
0.00
|
| Non Current Prepaid Assets |
|
0.03
+0.00%
|
0.03
|
| Other Non Current Assets |
|
0.10
+11.78%
|
0.09
|
| Total Liabilities Net Minority Interest |
|
2.24
-9.83%
|
2.48
|
| Current Liabilities |
|
1.90
+3.79%
|
1.83
|
| Payables And Accrued Expenses |
|
1.41
-8.53%
|
1.54
|
| Payables |
|
0.53
-31.28%
|
0.78
|
| Accounts Payable |
|
0.53
-31.28%
|
0.78
|
| Current Accrued Expenses |
|
0.87
+14.72%
|
0.76
|
| Current Debt And Capital Lease Obligation |
|
0.31
+7.73%
|
0.29
|
| Current Capital Lease Obligation |
|
0.31
+7.73%
|
0.29
|
| Current Deferred Liabilities |
|
—
|
—
|
| Current Deferred Revenue |
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.34
-48.18%
|
0.65
|
| Long Term Debt And Capital Lease Obligation |
|
0.34
-48.18%
|
0.65
|
| Long Term Capital Lease Obligation |
|
0.34
-48.18%
|
0.65
|
| Stockholders Equity |
|
5.12
-11.15%
|
5.77
|
| Common Stock Equity |
|
5.12
-11.15%
|
5.77
|
| Capital Stock |
|
0.00
+686.02%
|
0.00
|
| Common Stock |
|
0.00
+686.02%
|
0.00
|
| Share Issued |
|
2.59
+686.47%
|
0.33
|
| Ordinary Shares Number |
|
2.01
+511.70%
|
0.33
|
| Treasury Shares Number |
|
0.57
|
0.00
|
| Additional Paid In Capital |
|
173.09
+7.95%
|
160.34
|
| Retained Earnings |
|
-167.95
-8.66%
|
-154.57
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.02
-146.87%
|
-0.01
|
| Minority Interest |
|
—
|
—
|
| Other Equity Adjustments |
|
-0.02
-146.87%
|
-0.01
|
| Total Equity Gross Minority Interest |
|
5.12
-11.15%
|
5.77
|
| Total Capitalization |
|
5.12
-11.15%
|
5.77
|
| Working Capital |
|
4.05
-7.86%
|
4.40
|
| Invested Capital |
|
5.12
-11.15%
|
5.77
|
| Total Debt |
|
0.65
-30.90%
|
0.94
|
| Capital Lease Obligations |
|
0.65
-30.90%
|
0.94
|
| Net Tangible Assets |
|
5.12
-11.14%
|
5.77
|
| Tangible Book Value |
|
—
|
—
|
| Line Item | Trend | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.65
+24.52%
|
-10.13
+3.57%
|
-10.51
-7.56%
|
-9.77
|
| Cash Flow From Continuing Operating Activities |
|
-7.65
+24.52%
|
-10.13
+3.57%
|
-10.51
-7.56%
|
-9.77
|
| Net Income From Continuing Operations |
|
-13.39
-9.66%
|
-12.21
-1.48%
|
-12.03
-15.44%
|
-10.42
|
| Depreciation Amortization Depletion |
|
0.34
-5.43%
|
0.36
+49.05%
|
0.24
+94.76%
|
0.12
|
| Depreciation |
|
0.34
-5.44%
|
0.36
+49.17%
|
0.24
|
—
|
| Amortization Cash Flow |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
—
|
| Depreciation And Amortization |
|
0.34
-5.43%
|
0.36
+49.05%
|
0.24
+94.76%
|
0.12
|
| Amortization Of Intangibles |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
—
|
| Other Non Cash Items |
|
4.89
+3422326.57%
|
0.00
-99.41%
|
0.02
-20.06%
|
0.03
|
| Stock Based Compensation |
|
0.42
-65.95%
|
1.22
+15.92%
|
1.05
+40.14%
|
0.75
|
| Operating Gains Losses |
|
—
|
0.02
-85.13%
|
0.14
|
—
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.02
|
0.00
|
—
|
| Change In Working Capital |
|
0.09
-80.43%
|
0.48
+632.58%
|
0.07
+126.02%
|
-0.25
|
| Change In Receivables |
|
—
|
0.00
-100.00%
|
0.13
+505.98%
|
0.02
|
| Changes In Account Receivables |
|
—
|
0.00
-100.00%
|
0.13
+505.98%
|
0.02
|
| Change In Prepaid Assets |
|
0.11
+1213.40%
|
-0.01
-102.57%
|
0.40
+162.54%
|
-0.64
|
| Change In Payables And Accrued Expense |
|
-0.02
-104.14%
|
0.49
+520.56%
|
-0.12
-186.26%
|
0.13
|
| Change In Payable |
|
-0.02
-104.14%
|
0.49
+520.56%
|
-0.12
-186.26%
|
0.13
|
| Change In Account Payable |
|
-0.05
-134.06%
|
0.16
+189.67%
|
-0.17
-279.13%
|
0.10
|
| Change In Other Working Capital |
|
—
|
—
|
-0.34
-250.00%
|
0.23
|
| Investing Cash Flow |
|
0.00
+100.00%
|
-0.25
+73.40%
|
-0.94
-170.08%
|
-0.35
|
| Cash Flow From Continuing Investing Activities |
|
0.00
+100.00%
|
-0.25
+73.40%
|
-0.94
-170.08%
|
-0.35
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.25
+73.40%
|
-0.94
-170.08%
|
-0.35
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.25
+73.40%
|
-0.94
-170.08%
|
-0.35
|
| Capital Expenditure |
|
—
|
-0.25
+73.40%
|
-0.94
-170.08%
|
-0.35
|
| Gain Loss On Sale Of Business |
|
—
|
0.00
-100.00%
|
0.14
|
0.00
|
| Financing Cash Flow |
|
7.73
+500.14%
|
1.29
-85.56%
|
8.91
-48.67%
|
17.37
|
| Cash Flow From Continuing Financing Activities |
|
7.73
+500.14%
|
1.29
-85.56%
|
8.91
-48.67%
|
17.37
|
| Net Common Stock Issuance |
|
3.54
+167.69%
|
1.32
-85.19%
|
8.93
-48.86%
|
17.46
|
| Proceeds From Stock Option Exercised |
|
4.37
|
0.00
|
—
|
—
|
| Net Other Financing Charges |
|
-0.18
-428.45%
|
-0.03
-178.38%
|
-0.01
+85.82%
|
-0.09
|
| Changes In Cash |
|
0.08
+100.90%
|
-9.09
-258.91%
|
-2.53
-134.94%
|
7.25
|
| Effect Of Exchange Rate Changes |
|
-0.01
-681.96%
|
0.00
+135.37%
|
-0.01
|
—
|
| Beginning Cash Position |
|
5.53
-62.18%
|
14.62
-14.80%
|
17.16
+73.19%
|
9.91
|
| End Cash Position |
|
5.60
+1.26%
|
5.53
-62.18%
|
14.62
-14.80%
|
17.16
|
| Free Cash Flow |
|
-7.65
+26.35%
|
-10.38
+9.33%
|
-11.45
-13.17%
|
-10.12
|
| Common Stock Issuance |
|
3.54
+167.69%
|
1.32
-85.19%
|
8.93
-48.86%
|
17.46
|
| Issuance Of Capital Stock |
|
3.54
+167.69%
|
1.32
-85.19%
|
8.93
-48.86%
|
17.46
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-01 View
- 42026-04-01 View
- 42026-04-01 View
- 8-K2026-03-17 View
- 8-K2026-02-23 View
- 10-Q2026-02-12 View
- 8-K2026-02-12 View
- 8-K2026-01-26 View
- 42026-01-02 View
- 42026-01-02 View
- 42026-01-02 View
- 8-K2025-12-08 View
- 10-Q2025-11-12 View
- 8-K2025-11-12 View
- 8-K2025-11-06 View
- 8-K2025-10-22 View
- 8-K2025-10-16 View
- 42025-10-02 View
- 42025-10-02 View
- 42025-10-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|